• +91-20-26993900
  • serumexports@seruminstitute.com
medicate
  • Home
  • Overview
  • Symptoms
  • Causes
  • Complications
  • Prevention
  • Vaccine
  • Hajj/Umrah
  • Warnings
  • FAQ
  • Media
    • Video
  • Contact
SII

Video

  1. Home
  2. Media
  3. Video
235 million and counting: celebrating the success of the MenAfriVac vaccine (PATH)
View
History of MenAfriVac®, an affordable meningitis A vaccine tailor-made for Africa (1 minute) (PATH)
View
Manufacturing MenAfriVac™ (PATH)
View
Introduction of MenAfriVac® in the African Expanded Programme on Immunization (PATH)
View
History of MenAfriVac®, an affordable meningitis A vaccine tailor-made for Africa
View
The Making of MenAfriVac™ (PATH)
View
medicate-footer-logo

MenFive, the first Pentavalent Meningococcal conjugate vaccine to protect against the five predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO). Developed through a 13-year collaboration between Serum Institute of India Pvt. Ltd. (SIIPL) and PATH, with crucial funding from the UK government’s Foreign, Commonwealth and Development Office.

Links

  • Home
  • Hajj/Umrah
  • Overview
  • Warnings
  • Symptoms
  • FAQ
  • Causes
  • Media
  • Complications
  • Resources
  • Prevention
  • Contact
  • Vaccine

Contact Us

  • +91-20-26993900
  • serumexports@seruminstitute.com
  • 212/2, Hadapsar, Off Soli Poonawalla Road, Pune 411028 India
Copyright 2025 Serum Institute of india Pvt. Ltd